Literature DB >> 32939619

The value of MRI contrast enhancement in biopsy decision of suspicious mammographic microcalcifications: a prospective multicenter study.

Fusun Taskin1,2, Cem Burak Kalayci3, Nermin Tuncbilek4, Efe Soydemir5, Nazmi Kurt4, Handan Kaya6, Erkin Aribal7,8.   

Abstract

OBJECTIVES: To investigate the inclusion of breast MRI in radiological assessment of suspicious, isolated microcalcifications detected with mammography.
METHODS: In this prospective, multicenter study, cases with isolated microcalcifications in screening mammography were examined with dynamic contrast-enhanced MRI (DCE-MRI) before biopsy, and contrast enhancement of the relevant calcification localization was accepted as a positive finding on MRI. Six experienced breast radiologists evaluated the images and performed the biopsies. Imaging findings and histopathological results were recorded. Sensitivity, specificity, NPV, and PPV of breast MRI were calculated and compared with histopathological findings.
RESULTS: Suspicious microcalcifications, which were detected by screening mammograms of 444 women, were evaluated. Of these, 276 (62.2%) were diagnosed as benign and 168 (37.8%) as malignant. Contrast enhancement was present in microcalcification localization in 325 (73.2%) of the cases. DCE-MRI was positive in all 102 invasive carcinomas and in 58 (87.9%) of 66 DCIS cases. MRI resulted in false negatives in eight DCIS cases; one was high grade and the other seven were low-to-medium grade. The false-negative rate of DCE-MRI was 4.76%. The sensitivity, specificity, PPV, and NPV for DCE-MRI for mammography-detected suspicious microcalcifications were 95.2%, 40.2%, 49.2%, and 93.3%, respectively.
CONCLUSIONS: In this study, all invasive cancers and all DCIS except eight cases (12.1%) were detected with DCE-MRI. DCE-MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are of low-to-medium grade. KEY POINTS: • All invasive cancer cases and 87.8% of all in situ cancer cases were detected with MRI, showing a low false-negative rate of 4.7%. • Dynamic contrast-enhanced MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are predominantly low-to-medium grade. • If a decision for biopsy were made based on MRI findings in mammography-detected microcalcifications in this study, biopsy would not be performed to 119 cases (26.8%).

Entities:  

Keywords:  Breast cancer; Breast carcinoma in situ; Magnetic resonance imaging; Mammography

Mesh:

Year:  2020        PMID: 32939619     DOI: 10.1007/s00330-020-07265-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

1.  Usefulness of MRI of microcalcification lesions to determine the indication for stereotactic mammotome biopsy.

Authors:  Mariko Kikuchi; Hirokazu Tanino; Yoshimasa Kosaka; Norihiko Sengoku; Keishi Yamashita; Naoko Minatani; Hiroshi Nishimiya; Mina Waraya; Hiroshi Katoh; Takumo Enomoto; Sabine Kajita; Reiko Woodhams; Masahiko Watanabe
Journal:  Anticancer Res       Date:  2014-11       Impact factor: 2.480

2.  A comparative study of the diagnostic value of contrast-enhanced breast MR imaging and mammography on patients with BI-RADS 3-5 microcalcifications.

Authors:  Erni Li; Jing Li; Ying Song; Mei Xue; Chunwu Zhou
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

3.  MRI for the assessment of malignancy in BI-RADS 4 mammographic microcalcifications.

Authors:  Barbara Bennani-Baiti; Matthias Dietzel; Pascal A Baltzer
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

  3 in total
  1 in total

Review 1.  Stereotactic breast biopsy: A review & applicability in the Indian context.

Authors:  Suma Chakrabarthi
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.